Flash Finance

Shilpa Medicare LimitedSHILPAMEDCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹937.60
MCap ₹18,338 Cr · P/E 61.6
Shilpa Medicare Limited — Stock analysis & AI research Shilpa Medicare Limited — Multibagger AI analysis Shilpa Medicare Limited — Seasonality — best & worst months Shilpa Medicare Limited — Technical indicators & charts Shilpa Medicare Limited — Technical setup — score, trend, support & resistance Shilpa Medicare Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results📋 Small Cap Stocks List 📈 SuperTrend Bearish Signal📈 Relative Strength Leaders📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹466 Cr
Sales · Jun 2026
+44.9% YoY
₹136 Cr
Operating Profit · Jun 2026
+48.7% YoY
29.3%
OPM % · Jun 2026
+2.8% YoY
₹101 Cr
Net Profit · Jun 2026
+115.2% YoY
₹5.16
EPS · Jun 2026
+7.7% YoY

📝 Shilpa Medicare Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Shilpa Medicare Limited reported revenue of ₹466 crore for the quarter ended June 2026 (Q1 FY27), up 44.9% from ₹321 crore in the same quarter last year, and up 6.6% sequentially over the March 2026 quarter.

Net profit rose 115.2% year-on-year to ₹101 crore, from ₹47 crore. Earnings per share (EPS) came in at ₹5.16.

Operating profit stood at ₹136 crore — an operating margin (OPM) of 29.3%, compared with 28.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Shilpa Medicare Limited posted revenue of ₹1,538 crore, a growth of 47.7% over FY25, with a net profit of ₹243 crore (up 454.9% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,683 crore with a net profit of ₹297 crore.

Valuation snapshot

At the current price of ₹937.60, SHILPAMED has a market capitalisation of ₹18,338 crore and a trailing P/E of about 61.6.

Within the Pharmaceuticals - Indian - Formulations industry, it is the largest of the 20 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 40.13%, foreign institutional investors (FIIs) 12.11%, domestic institutional investors (DIIs) 8.26%, public shareholders 39.49% of Shilpa Medicare Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹18,338 Cr
Current Price ?
₹937.6
P/E ?
61.65above ind
Industry P/E ?
21.30
P/B ?
7.07
P/S ?
10.90
P/FCF ?
-1,222.52
Enterprise Value ?
₹18,998 Cr
EV/EBITDA ?
39.70
PEG ?
0.57
Earnings Yield ?
1.9%
Dividend Yield ?
0.05%
Profitability & Returns
Sales (TTM) ?
₹1,683 Cr
OPM ?
28.4%
Profit after tax (TTM) ?
₹297 Cr
EPS (TTM) ?
₹15.21
ROCE ?
11.0%
ROE ?
11.5%
ROA ?
8.0%
Growth
Sales — latest qtr ?
₹466 Cr
PAT — latest qtr ?
₹101 Cr
YoY qtr sales growth ?
44.9%
YoY qtr profit growth ?
115.2%
Sales growth (3y) ?
14%
Sales growth (5y) ?
11%
Profit growth (3y) ?
109%
Profit growth (5y) ?
18%
Financial Health
Debt ?
₹660 Cr
Debt to Equity ?
0.25
Interest Coverage ?
5.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
40.13%
Change in promoter holding ?
-4.10%
Pledged percentage ?
N/A
Market
Return 3 months ?
51.2%
Return 6 months ?
128.4%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 26226426031328629247344319331321370410437466 +44.9% +6.6%
Operating Profit 313748586670-2586817792108114120136 +48.7% +13.5%
Other Income 32222931518621453 -50.9% -93.0%
Interest 18181823262422612141916111412 -35.6% -13.6%
Depreciation 242627282727122829292930303135 +21.7% +13.5%
Profit Before Tax -8-4391428-837421550646112098 +97.8% -18.3%
Net Profit -7-812524-20183215474445108101 +115.2% -6.6%
EPS -0.76-0.460.140.090.531.41-2.941.833.251.484.792.252.365.515.16 +7.7% -6.4%
OPM % 11.9% 14.0% 18.4% 18.5% 23.0% 24.0% -52.2% 25.0% 25.3% 23.2% 28.5% 29.2% 27.9% 27.5% 29.3% +2.8% +6.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,041 Cr ₹1,538 Cr ₹1,683 Cr +47.7%
Operating Profit ₹219 Cr ₹434 Cr ₹479 Cr +98.4%
OPM % 21.00% 28.21% 28.44% +34.3%
NPM % 4.21% 15.83% 17.68% +276.0%
Other Income ₹45 Cr ₹54 Cr ₹51 Cr +20.0%
Depreciation ₹98 Cr ₹120 Cr ₹127 Cr +22.5%
Interest ₹54 Cr ₹59 Cr ₹53 Cr +10.6%
EBIT ₹121 Cr ₹314 Cr ₹352 Cr +160.2%
PBT ₹86 Cr ₹294 Cr ₹343 Cr +243.8%
Tax ₹42 Cr ₹19 Cr ₹13 Cr -54.6%
Net Profit ₹44 Cr ₹243 Cr ₹297 Cr +454.9%
EPS ₹3.62 ₹14.91 ₹15.28 +311.9%
Material Cost ₹308 Cr ₹227 Cr ₹261 Cr -26.4%
Employee Cost ₹247 Cr ₹165 Cr ₹183 Cr -33.1%
Extraordinary Items ₹28 Cr ₹-13 Cr ₹-13 Cr -146.6%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 991020 +100.0%
Reserves 1,7751,8002,3622,572 +8.9%
Borrowings 798937588660 +12.2%
Other Liabilities 323347351455 +29.6%
Total Liabilities 2,9043,0933,3113,706 +11.9%
Fixed Assets 1,3681,3851,4182,046 +44.3%
CWIP 655719822431 -47.6%
Investments 43403558 +65.7%
Other Assets 8389501,0371,170 +12.8%
Total Assets 2,9043,0933,3113,706 +11.9%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 180137132342 +159.1%
Cash from Investing Activity -232-171-198-326 -64.6%
Cash from Financing Activity 46476314 -77.8%
Net Cash Flow -713-330 +1100.0%
Free Cash Flow -46-48-111-15 +86.5%
CFO/OP 215%74%57%93% +63.2%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 113125126123 -2.4%
Inventory Days 280309309291 -5.8%
Days Payable 12515685113 +32.9%
Cash Conversion Cycle 268278350301 -14.0%
Working Capital Days -13488151 -37.0%
ROCE % 1%5%8%11% +37.5%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 44.23%44.23%40.13%40.13%40.13% +0.0%
FIIs 11.19%10.92%10.97%11.07%12.11% +9.4%
DIIs 7.46%7.67%8.34%8.58%8.26% -3.7%
Public 37.10%37.18%40.56%40.21%39.49% -1.8%
No. of Shareholders 48,63652,06553,79953,41087,477 +63.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Shilpa Medicare Limited's revenue in Q1 FY27?
Shilpa Medicare Limited reported revenue of ₹466 crore for the quarter ended June 2026 (Q1 FY27), up 44.9% from ₹321 crore in the same quarter last year, and up 6.6% sequentially over the March 2026 quarter.
What was Shilpa Medicare Limited's net profit in Q1 FY27?
Net profit rose 115.2% year-on-year to ₹101 crore, from ₹47 crore. Earnings per share (EPS) came in at ₹5.16.
What is SHILPAMED's market capitalisation and P/E ratio?
At the current price of ₹937.60, SHILPAMED has a market capitalisation of ₹18,338 crore and a trailing P/E of about 61.6.
Who owns Shilpa Medicare Limited? (shareholding pattern)
As of Sep 2026, promoters held 40.13%, foreign institutional investors (FIIs) 12.11%, domestic institutional investors (DIIs) 8.26%, public shareholders 39.49% of Shilpa Medicare Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI